Camarus AB (STO:CAMX) and Braeburn Pharmaceuticals said this week that a late-stage trial of its injectable opioid dependence treatment was successful. CMAX shares surged 16% at the beginning of the week following the announcement.
The injectable buprenorphine therapy could be another treatment used to combat the growing opioid epidemic in the United States, which claimed the lives of more than 47,000 Americans in 2014, according to the Wall Street Journal. In that same year, 650,000 Americans received buprenorphine to treat opioid addiction.
Get the full story at our sister site, Drug Delivery Business News
The post Injectable opioid dependence treatment succeeds in clinical trial appeared first on MassDevice.
from MassDevice http://ift.tt/2eWVdep
Cap comentari:
Publica un comentari a l'entrada